Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-05-29
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00061464
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Columbia, South Carolina, United States
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
- Conditions
- Mesothelioma
- First Posted Date
- 2003-05-29
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00061477
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2003-05-29
- Last Posted Date
- 2010-12-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00061451
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Great Falls, Montana, United States
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Cardiovascular DiseasesHeart Diseases
- Interventions
- First Posted Date
- 2003-04-23
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 905
- Registration Number
- NCT00059215
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Boston, Massachusetts, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, British Columbia, Canada
A Study for the Treatment of Painful Diabetic Neuropathy
- Conditions
- Diabetic Neuropathy, Painful
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2007-05-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 660
- Registration Number
- NCT00058968
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLilly (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pembroke Pines, Florida, United States
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
- Conditions
- Ovarian CancerPeritoneal Cancer
- First Posted Date
- 2003-03-04
- Last Posted Date
- 2006-09-15
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00055432
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Atlanta, Georgia, United States
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- Biological: Cetuximab
- First Posted Date
- 2003-03-04
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 744
- Registration Number
- NCT00055419
- Locations
- 🇺🇸
ImClone Investigational Site, Green Bay, Wisconsin, United States
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2003-02-24
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00055250
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Lakeland, Florida, United States
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00051909
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 428
- Registration Number
- NCT00051558
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ponce, Puerto Rico